Cytryn Samuel L, Janjigian Yelena Y
Memorial Sloan Kettering Cancer Center, New York, New York.
J Natl Compr Canc Netw. 2023 Apr;21(4):423-429. doi: 10.6004/jnccn.2023.7010.
HER2 is overexpressed in approximately 20% of esophagogastric cancer (EGC) cases. The addition of the anti-HER2 antibody, trastuzumab, to chemotherapy in 2010 was the first targeted treatment to demonstrate an improvement in survival. The aggressive nature and heterogeneous biology of EGC have posed a particular challenge and resulted in numerous negative trials without a change in standard of care for more than a decade. However, with the incorporation of dual HER2 and PD-1 blockade as well as the advent of a new, potent antibody-drug conjugate, trastuzumab deruxtecan, there have been 2 new FDA approvals for this patient population within the past 2 years. Consequently, the management and landscape of HER2-positive EGC is rapidly changing and increasingly optimistic.
人表皮生长因子受体2（HER2）在约20%的食管胃癌（EGC）病例中过表达。2010年，在化疗中添加抗HER2抗体曲妥珠单抗是首个显示能改善生存率的靶向治疗。EGC的侵袭性本质和异质性生物学特性带来了特殊挑战，导致十多年来众多试验结果为阴性，且护理标准未发生改变。然而，随着HER2和程序性死亡受体1（PD-1）双重阻断疗法的纳入，以及新型强效抗体药物偶联物曲妥珠单抗德曲妥珠单抗的出现，在过去两年里，针对这一患者群体有两项新的药物获得美国食品药品监督管理局（FDA）批准。因此，HER2阳性EGC的治疗和前景正在迅速改变，且越来越令人乐观。
